Since March 2020, we have been working on the repositioning of a drug against CoViD19, alongside two research teams from Lille. The implementation of our technologies and our know-how has made it possible to highlight the antiviral potential of an active principle of a drug already marketed in Europe in another indication. It is now necessary to demonstrate the medical interest through a clinical trial which will take place in the Hauts de France territory, Therapide, promoted by the Institut Pasteur de Lille and led by Professor Benoit Deprez.
The “National Research Priority” label, granted by Capnet, notably allows exclusive access to an accelerated procedure for evaluating the regulatory authorization file by the ethical Committee and the National Security Agency of Medicines and health products (ANSM).
The clinical trial is the last step to judge the medicinal usefulness of the drug before we can enrich our therapeutic arsenal against CoViD19 alongside vaccines.
About the partner research teams: M2SV U1177 – Institut Pasteur de Lille, Inserm, University of Lille, directed by Professor Benoit Deprez and CIIL UMR9017 – Institut Pasteur de Lille, University of Lille, CNRS, Inserm, CHU de Lille, directed by Professor Jean Dubuisson.
In the picture, TEELibrary, our collection of molecules tested on the virus and containing TEE001 the drug identified in the spring of 2020.
